443 related articles for article (PubMed ID: 17650420)
21. Differences between graft product and donor side effects following bone marrow or stem cell donation.
Favre G; Beksaç M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szer J; Bradstock K; Buzyn A; Matcham J; Gratwohl A; Schmitz N;
Bone Marrow Transplant; 2003 Nov; 32(9):873-80. PubMed ID: 14561987
[TBL] [Abstract][Full Text] [Related]
22. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
23. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.
Sartor MM; Garvin F; Antonenas V; Bradstock KF; Gottlieb DJ
Bone Marrow Transplant; 2007 Nov; 40(9):851-7. PubMed ID: 17704793
[TBL] [Abstract][Full Text] [Related]
24. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation.
Huang X; Guo N; Ren H; Zhang Y; Gao Z; Lu D
Chin Med J (Engl); 2003 May; 116(5):736-41. PubMed ID: 12875692
[TBL] [Abstract][Full Text] [Related]
25. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
[TBL] [Abstract][Full Text] [Related]
26. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.
Statkute L; Verda L; Oyama Y; Traynor A; Villa M; Shook T; Clifton R; Jovanovic B; Satkus J; Loh Y; Quigley K; Yaung K; Gonda E; Krosnjar N; Spahovic D; Burt RK
Bone Marrow Transplant; 2007 Mar; 39(6):317-29. PubMed ID: 17277794
[TBL] [Abstract][Full Text] [Related]
27. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
[TBL] [Abstract][Full Text] [Related]
28. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.
Allan DS; Keeney M; Howson-Jan K; Popma J; Weir K; Bhatia M; Sutherland DR; Chin-Yee IH
Bone Marrow Transplant; 2002 Jun; 29(12):967-72. PubMed ID: 12098064
[TBL] [Abstract][Full Text] [Related]
29. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of 2 children with mucopolysaccharidosis by allogeneic hematopoietic stem cell transplantation].
Chen J; Jiang H; Dong L; Wang Y; Luo C; Zhou M; Zhang W; Huang S; Gu X; Qiu W; Zhang H; Gu L
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):675-7. PubMed ID: 19065530
[TBL] [Abstract][Full Text] [Related]
32. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
Rizzieri DA; Talbot JT; Long GD; Vredenburgh JJ; Gasparetto C; Smith CS; Colvin MO; Adams D; Morris A; Dodge R; Loftis J; Waters-Pick B; Reese M; Carawan H; Koh LP; Chao NJ
Biol Blood Marrow Transplant; 2003 Mar; 9(3):183-8. PubMed ID: 12652469
[TBL] [Abstract][Full Text] [Related]
33. [Effectiveness of allogeneic peripheral blood stem cell transplantation in 23 patients with myelodysplastic syndromes].
Hu LD; Chen H; Jiang M; Li BT; Qin MQ; Yu ZY; Li YH
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):522-4. PubMed ID: 17172124
[TBL] [Abstract][Full Text] [Related]
34. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
35. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
[TBL] [Abstract][Full Text] [Related]
37. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
Toor AA; Choo SY; Little JA
Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood stem cell apheresis for allogeneic transplants: Ibni Sina experience.
Arat M; Arslan O; Ayyildiz E; Topcuoglu P; Dalva K; Ilhan O
Transfus Apher Sci; 2004 Jun; 30(3):189-91. PubMed ID: 15172622
[TBL] [Abstract][Full Text] [Related]
39. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
[TBL] [Abstract][Full Text] [Related]
40. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
